Effects of dezocine on prevention of propofol injection pain: a meta-analysis
Authors Zhou C, Yang Y, Zhu Y, Ruan L
Received 28 November 2016
Accepted for publication 5 May 2017
Published 1 June 2017 Volume 2017:10 Pages 1369—1375
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Michael Schatman
Chengmao Zhou,1,* Yuting Yang,2,* Yu Zhu,3 Lin Ruan4
1Department of Anesthesiology, Zhaoqing Medical College, Zhaoqing, 2Department of Oncology, The First People’s Hospital of Changde, Changde, 3Department of Nursing, Zhaoqing Medical College, Zhaoqing, 4Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China
*These authors contributed equally to this work
Objective: The objective of this study was to evaluate the effects of dezocine on the prevention of propofol injection pain.
Materials and methods: We searched for randomized controlled trials (RCTs) of dezocine in preventing propofol injection pain, from inception to April 2016, in PubMed, Embase, Cochrane Library, and CNKI. Next, two reviewers independently screened literature, extracted data, and assessed quality in accordance with the inclusion and exclusion criteria. Finally, RevMan 5.2 software was used to conduct a meta-analysis.
Results: Seven RCTs totaling 630 patients were included in this meta-analysis. The meta-analysis study showed: 1) compared with the control group (relative risk [RR] =0.32, 95% CI [0.26, 0.39], P<0.00001), the dezocine group showed a decreasing incidence of propofol injection pain; 2) for severity of propofol injection pain, incidences of mild pain (RR =0.55, 95% CI [0.40, 0.75], P=0.0001), moderate pain (RR =0.28, 95% CI [0.18, 0.43], P<0.00001), and severe pain (RR =0.11, 95% CI [0.06, 0.23], P<0.00001) were considerably lower in the dezocine group than in the control group; 3) when comparing the incidence of propofol injection pain in the dezocine group with that of the lidocaine group, no statistically significant differences were found (RR =0.86, 95% CI [0.66, 1.13], P=0.29); and 4) subgroup analysis indicated a significant reduction in the incidence of propofol injection.
Conclusion: Dezocine can both prevent propofol injection pain and mitigate its severity, and its efficacy shows no significant difference from that of lidocaine.
Keywords: dezocine, propofol injection pain, meta-analysis, randomized controlled trials
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]